» Articles » PMID: 28210109

Astragalus-containing Chinese Herbal Combinations for Advanced Non-small-cell Lung Cancer: a Meta-analysis of 65 Clinical Trials Enrolling 4751 Patients

Overview
Publisher Dove Medical Press
Date 2017 Feb 18
PMID 28210109
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-small-cell lung cancer (NSCLC) is a leading cause of death. Interventions to reduce mortality in patients with NSCLC represent a patient-important field of research. Little is known about interventions used outside the Western world for NSCLC. One intervention widely used in Asia is astragalus-based herbal preparations.

Methods: We conducted a comprehensive systematic review of all published randomized clinical trials (RCTs) evaluating astragalus-based herbal preparations in NSCLC patients. We searched independently, in duplicate, 6 English language electronic databases and 2 Chinese-language databases. We abstracted data independently, in duplicate on studies reporting of methods, survival outcomes, tumor responses, and performance score responses. We applied a random-effects meta-analysis and report outcomes as relative risks (RR) with 95% confidence intervals (CIs).

Results: We included 65 RCTs enrolling 4751 patients. All trials included the herbal preparations plus platinum-based chemotherapy versus chemotherapy alone. We pooled 7 studies (n = 529) reporting on survival at 6 months and found a pooled RR of 0.54 (95% CI, 0.45 to 0.65, ≤ 0.0001). We included 20 trials (n = 1520) on survival at 12 months and found a pooled RR of 0.65 (95% CI, 0.54 to 0.79, ≤ 0.0001). This effect was consistent at 24 and 36 months. When we applied a composite endpoint of any tumor treatment response, we pooled data from 57 trials and found a pooled RR of 1.35 in favor of herbal treatment (95% CI, 1.26 to 1.44, ≤ 0.0001). Statistical heterogeneity was low across trials.

Limitations: The quality of reporting the RCTs was generally poor. There is also reason to believe that studies reported as randomized may not be.

Conclusions: We found a large treatment effect of adding astragalus-based herbal treatment to standard chemotherapy regimens. There is a pressing need for validation of these findings in well-conducted RCTs in a Western setting.

Citing Articles

Medicinal Plants and Mushrooms with Immunomodulatory and Anticancer Properties-A Review on Hong Kong's Experience.

Yue G, Lau C, Leung P Molecules. 2021; 26(8).

PMID: 33918834 PMC: 8068888. DOI: 10.3390/molecules26082173.


Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study.

Kim E, Yoon J, Yoon S, Lee J, Yoon S Integr Cancer Ther. 2020; 19:1534735420983457.

PMID: 33349074 PMC: 7758658. DOI: 10.1177/1534735420983457.


The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

Dedong C, Huilin X, Anbing H, Ximing X, Wei G PLoS One. 2016; 11(3):e0152270.

PMID: 27015629 PMC: 4807845. DOI: 10.1371/journal.pone.0152270.


The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Li S, Chen H, Ou-Yang C, Wang X, Yang Z, Tong Y PLoS One. 2013; 8(2):e57604.

PMID: 23469033 PMC: 3585199. DOI: 10.1371/journal.pone.0057604.

References
1.
Liu L, Liu J, Li C . [Clinical effect of yiqi yangyin jiedu decoction in treating patients with advanced non-small cell lung cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008; 28(4):352-5. View

2.
Chu D, Wong W, Mavligit G . Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol. 1988; 25(3):125-9. View

3.
Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

4.
Wu T, Li Y, Bian Z, Liu G, Moher D . Randomized trials published in some Chinese journals: how many are randomized?. Trials. 2009; 10:46. PMC: 2716312. DOI: 10.1186/1745-6215-10-46. View

5.
Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View